ResMed Inc. reported first-quarter fiscal year 2027 revenue of $1.4 billion, representing a 6% increase compared to the prior-year period. GAAP diluted earnings per share rose 23% to $2.92, while the board declared a quarterly cash dividend of $0.66 per share.
Q1 revenue increased 6% to $1.4 billion, or 7% on a core constant currency basis.
GAAP diluted earnings per share grew 23% to $2.92, and non-GAAP diluted EPS rose 14% to $2.91.
The board of directors declared a quarterly cash dividend of $0.66 per share, payable on December 17, 2026, with a record date of November 12, 2026.
The company returned more than $1.0 billion to shareholders through share repurchases and dividends during the quarter.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From ResMed's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2026
$5.65B
+9.9%
$10.43
+9.7%
26.9%
FY2025
$5.15B
+9.8%
$9.51
+37.4%
27.2%
FY2024
$4.69B
+10.9%
$6.92
+13.6%
21.8%
FY2023
$4.22B
+18.0%
$6.09
+14.9%
21.3%
FY2022
$3.58B
+11.9%
$5.30
+63.6%
21.8%
Frequently asked questions
When is ResMed's next earnings date?
ResMed has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did ResMed earn last quarter?
For the quarter ended Sep 2026, ResMed reported diluted EPS of $2.92 (+23.2% year over year) on revenue of $1.41B (+5.9%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.